First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.

Nobutaka NishimuraMakito MiyakeTakuto ShimizuToshihiko MatsubaraTatsuki MiyamotoKeichi SakamotoAtsushi YamadaYoshihiro MatsumotoMotokiyo YoshikawaKazuki IchikawaChihiro OmoriFumisato MaesakaYuki OdaKeisuke KibaAtsushi TomiokaYukinari HosokawaMasahiro TanakaTakeshi OtaniKiyohide Fujimoto

Published in: International journal of clinical oncology (2022)

First-line pembrolizumab in earlier clinical settings for highly malignant tumors might improve the prognosis of patients with early relapsing disease after the receipt of platinum-based perioperative chemotherapy.

Keyphrases

multiple sclerosis
urinary tract
cardiac surgery
patients undergoing
locally advanced
advanced non small cell lung cancer
papillary thyroid
disease activity
squamous cell carcinoma
squamous cell
rheumatoid arthritis
acute kidney injury
young adults
childhood cancer
tyrosine kinase